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Pharmacology of angiotensin II receptors in the kidney. Within the
kidney angiotensin II (Ang II) exerts potent effects on renal function. The
intrarenal actions of Ang II include modulation of renal blood flow,
glomerular filtration rate, tubular epithelial transport, renin release and
cellular growth. The actions of Ang 11 on the kidney are mediated by
specific intrarenal receptors which, based upon physical characteristics
and the selective binding of non-peptide and peptide analogs may be
divided into two main subtypes, termed AT1 and AT2. AT1 receptors are
present within the kidneys of all species and are located predominantly in
the glomerulus, the renal tubules and the renal vasculature, including the
afferent and efferent arterioles. Modulation of AT1 receptors within the
kidney has been shown to mediate essentially all of the known intrarenal
effects of Ang II. AT1 receptors and particularly AT2 receptors are
expressed in large numbers in fetal kidney where they may play a role in
development and maturation, In some species, intrarenal AT2 receptors
disappear shortly after birth. In those species where AT2 receptors are
present in the adult kidney their role in the control of renal function has
not yet been clearly defined.
Within the kidney angiotensin II (Ang II) exerts potent effects
on renal function. The intrarenal actions of Ang II include
modulation of renal blood flow, glonierular filtration rate, tubular
epithelial transport, renin release and cellular growth. Ang II
binding sites have been localized in the kidney using in vitro
autoradiography and in many cases have been correlated to
changes in physiological function [1—3]. Variations in structural
activity requirements and differences in signal transduction and
regulatory mechanisms in several of the intrarenal actions of Ang
II have been noted over the years [3]. These observation have led
to the suggestion that the actions of Ang II within the kidney are
mediated by different receptor subtypes. The recent availability of
new peptide and non-peptide ligands has allowed this hypothesis
to be confirmed with the unambiguous characterization of at least
two distinct Ang II receptor subtypes [4]. The pharmacology of
Ang II receptors subtypes within the kidney are summarized in
the following brief review.
Characteristics of Ang II receptor subtypes
Recently, two receptor subtypes having clearly different binding
characteristics were described in aortic smooth muscle, uterus and
adrenal cortex [5, 6]. These initial observations have since been
confirmed in a large number of tissues including the kidney [7—10].
Mg II receptors having a high affinity for losartan but a low
affinity for CGP 42112 and PD 123319 are termed AT1; whereas,
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Mg II receptors with a high affinity for CGP 42112 and PD
123319 but a low affinity for losartan are termed AT2 [11].
The distribution of AT1 and AT2 receptor subtypes is hetero-
geneous between tissues, Some tissues, for example the liver and
vascular smooth muscle cells in culture, express only the AT1
receptor [5, 8], whereas only the AT2 receptor is expressed in
cerebellum, ovary follicles or the human uterus [5, 12, 13]. In
some tissues, of which the adrenal cortex and heart are examples,
both the AT1 and AT2 receptor subtypes are expressed [5, 7].
Three major characteristics distinguish the AT1 and AT2 re-
ceptor subtypes. Firstly, sulfhydril reducing agents such as dithio-
threitol decrease the binding affinity of Mg II for the AT1 recep-
tor, whereas they increase the affinity of Mg II for the AT2
receptor [11]. Secondly, in contrast to the AT1 receptor, the
AT2 receptor does not appear to be coupled to a classical
G-protein [14]. Finally, the AT1 receptor-Mg II complex is
rapidly internalized within cells, whereas the complex of Mg II
with the AT2 receptor is not [15, 16].
Both the AT1 and AT2 receptor have been cloned and are
members of the 7-transmembrane domain superfamily, but have
only a 30 to 35% amino acid sequence identity [17—20]. It has been
clearly established that the AT1 receptor is coupled to phospho-
lipase C, adenylate cyclase and voltage-dependent calcium chan-
nels [21]. In contrast, the coupling mechanism of the AT2 receptor
has not yet been clearly defined, although evidence is accumulat-
ing to suggest linkage to a protein tyrosine phosphatase [14, 20].
Ang II receptor subtypes in the kidney
Autoradiography coupled with competitive binding studies
have been used to characterize the distribution of Ang II receptor
subtypes in renal tissue. Using these techniques, the distribution
of AT1 and AT2 receptor subtypes within the kidney has been
shown to be species dependent. For example, in the rat and rabbit
kidney Mg II receptors are essentially of the AT1 subtype [10,
22—24] while both AT1 and AT2 receptors are present within the
kidney of the opossum and of primates including humans [23—26].
The distribution of renal Mg II receptors has been most exten-
sively studied in the rat where the AT1 receptor subtype is
predominantly located in the glomerulus, the renal tubules and
the renal vasculature [27—29]; these observations have been
confirmed using reverse transcriptase, polymerase chain reactions
and in situ hybridization [30—32]. In these latter studies, large
signals for the AT1 receptor were detected in the glomerulus,
renal papilla, proximal convoluted tubule, proximal straight tu-
bule, cortical collecting duct and the renal vascular system.
Smaller signals for the AT1 receptor have also been detected in
medullary thick ascending limb, outer collecting duct and the
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Fig. 1. Effect of PD 123319 (U) and CGP
42112B (0) in comparison to losartan (0) on
parameters of renal function in the sodium-
depleted anesthetized rat. The results represent
the changes in each parameter of renal function
produced by CGP 42112B, PD 123319 and
losartan relative to baseline values. Statistics
compare the changes in each parameter at each
dose of drug relative to control values. The
methodology and detailed results of these
experiments have been previously described
[54]. Reprinted with permission from the
European Journal of Phannacology [54].
0
P<0.05
a)
0(a
p
0
w
2
0
—2
3
P<0.05
P<0.05
I I I
J
Pc0.05
-6
1
0
—1
a)
C0
a)E0
Control 1 10
Log dose
mg/kg
Control 1 10 100 1000
Log dose
(pg/kpJmin)
1488
a) .
0
a)0
(a—
00
F
10
B
Log dose
mg/kg
de Gasparo and Levens: Renal Ang II receptors
P<0.05
Log dose
(pg/kg/mm)
inner medullary collecting duct. Within the glomerulus, AT1
mRNA localizes in mesangial areas, predominantly at the vascular
pole and on the terminal portion of the afferent arteriole. In
contrast, intense staining in all small arteries and arterioles,
including both afferent and efferent arterioles has been observed
using polyclonal antisera raised against a peptide sequence of the
rat AT1 receptor 331-
in agreement with conclusions derived from autoradiography
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and receptor binding studies, AT2 mRNA has not been detected
by Northern blot analysis in the rat kidney [20]. However, in the
rabbit the fibrous sheath around the kidney contains an exclusive
population of AT2 receptors [34]. In contrast to the rat and the
rabbit, the AT2 receptor subtype has been demonstrated in the
renal cortex of the rhesus monkey on the intrarenal vasculature
and on the juxtaglomerular apparatus [23]. In human kidney, the
AT2 receptor subtype is clearly present in large preglomerular
vessels of the renal cortex and in the tubulointerstitium [26, 28].
Heterogeneity of renal Ang II receptor subtypes
Only a single gene encoding for the AT1 receptor is expressed
in human kidney [35, 36]. However, in rat kidney, as well as other
tissues from this species, two clones encoding for different AT1
receptor subtypes have been identified from genomic libraries
[37]. These AT1 receptor clones termed ATIA and AT1 have
over 90% identity but differ in their amino acid sequence,
primarily in the last intracellular ioop of the receptor. Both
receptor subtypes have essentially similar binding signatures and
are pharmacologically indistinguishable from each other [38].
ATSA and AT1 more accurately describe isoforms rather than
distinct subtypes of the Ang II receptor. The distribution of AT1A
and AT1B receptor isoforms within the kidney have not been
extensively studied although the AT1A receptor, which is ex-
pressed predominantly in vascular smooth muscle, is most abun-
dant in the glomerular mesangial area, the vascular component of
the juxtaglomerular apparatus and the terminal portion of the
afferent arteriole [31].
Receptor binding studies have also suggested the existence of
two AT1 receptor subpopulations in cultured rat mesangial cells
[39]. One subpopulation, which has been termed AT1A, represents
86% of the total number of binding sites and has a high affinity for
losartan but a low affinity for CGP 42112 and PD123319. This
receptor subtype thus resembles the AT1A isoform described
determined using molecular biology techniques and reported
above. The remaining 14% of binding sites which have unfortu-
nately been termed AT1B have a 100-fold lower affinity for
losartan and a 10'OOO-fold higher affinity for PD 123319 [39]. This
latter subtype, despite its high affinity for PD 123319, differs from
the typical AT2 receptor subtype in having a low affinity for CGP
42112B and being coupled to a G-protein. Furthermore, since the
AT1B receptor subtype described by receptor binding methodol-
ogy has remarkably different binding properties to the AT1B
receptor subtype described by molecular biology techniques they
must be structurally distinct. The description of subgroups of Ang
II receptors within the kidney which are clearly different but with
similar labeling is confusing and requires standardization.
All AT1 subtypes in the kidney are sensitive to G1'P analogues
and pertussis toxin and are linked to 1P3 generation, calcium
mobilization and adenylate cyclase inhibition [10, 28, 39, 40].
Mesangial AT1A receptors appear to mediate Ang II induced
protein synthesis [41].
Binding studies performed with radioactive losartan in isolated
rat glomeruli have demonstrated that in addition to labeling the
AT1 binding site, losartan may also recognize an additional
receptor with characteristics different from known AT1 or AT2
receptors [29]. The significance of this observation is unclear at
the present time.
Renal Ang II receptors during development
Within the kidney as well as in other tissues, both AT1 and AT2
receptors are developmentally regulated [9,42]. The AT2 receptor
subtype predominates in tissues of the developing rat and human
fetus, where they have a predominantly glomerular and medullary
distribution [43, 44]. Although less numerous, AT1 receptors are
also present in the developing rat kidney. With increasing devel-
opment AT2 receptors disappear and the AT1 receptor increases
in number to become, at least in rat kidney, the predominant
receptor subtype. Since all components of the renin-angiotensin
system are present within the developing fetal/placental unit and
Ang II plays a role in cell growth it has been suggested that Ang
II acting through AT2 receptors and perhaps also AT1 receptors
contribute to the growth and development of the immature
kidney. This hypothesis is supported by the recent observation
that treatment of fetal rats with either an angiotensin converting
enzyme inhibitors or an AT1 receptor antagonists leads to abnor-
malities of renal growth and to persistent defects in renal function
in the adult animal [45].
Changes in renal function mediated by Ang II receptors
AT1 receptors
Consistent with the intrarenal distribution described above,
AT1 receptors have been shown to mediate essentially all of the
known effects of Ang II on kidney function [46—50]. The intrare-
nal actions of Ang II mediated by AT1 receptors include vasocon-
striction, alterations in glomerular hemodynamics and tubular
reabsorption. AT1 receptors present upon juxtaglomerular appa-
ratus also mediate the negative feedback of Ang II on renin
release and renal cell growth [23, 51].
AT2 receptors
In contrast to the wealth of knowledge concerning the func-
tional role of intrarenal Ang II receptors, little is known concern-
ing the actions of Ang II mediated through the AT2 receptor.
There have been several reports suggesting that AT2 ligands can
affect renal function. For example, the AT2 receptor ligands PD
123177 and PD 123319 have been shown to antagonize the renal
vasoconstrictor response to exogenous Ang II and to induce an
increase in urine volume and free water formation in the anes-
thetized dog [52]. Furthermore, in the conscious rat, PD 123177
has been shown to increase renal blood flow following experimen-
tal myocardial infarction and in the anaesthetized rat to increase
glomerular filtration rate, urine volume, chloride and bicarbonate
excretion [46, 53]. Since in the aforementioned studies, PD
123177 and PD 123319 were used at very high doses and in the
majority of cases produced effects qualitative similar to AT1
receptor antagonists, the possibility exists that PD 123177 and PD
123319 influence renal function by interacting with the AT1
receptor or may exhibit non-specific properties. Both PD 123177
and PD 12319 are closely related compounds, and studies of renal
function with other ligands selective for the AT2 receptors have
not yet been performed. Therefore it is unknown whether the
renal actions of PD 123177 and PD 123319 are specific for this
class of compounds or are a property of all ligands selective for
the AT2 receptor. Recently the role of AT2 receptors in the
control of kidney function has been reassessed using the highly
selective AT2 ligand CGP 42112 [54]. In these experiments, the
renal actions of CGP 42112 in comparison to PD 123319 and
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losartan were investigated in sodium-depleted anesthetized rats.
The results in Figure 1 illustrate that PD 123319 at infusion rates
of ito 1000 g!kg/min had no effect on renal function, while CGP
42112 affected renal function only at an infusion rate of 1000
g/kg/min. During these experiments the plasma levels of both
compounds was monitored and compared to their known affinities
for AT1 and AT2 receptors. Assuming the plasma concentrations
of COP 421 12B and PD 123319 to be in equilibrium with those at
the receptor level then at an infusion rates of 1 and 1000
g/kg/min PD 123319 (plasma levels 70 nM and 25 MM, respec-
tively) would be expected to interact essentially with an exclusive
population of AT2 receptors. At doses between 1 and 100
g/kg/min, CGP 42112 (plasma levels of 14 and 700 flM, respec-
tively) would be expected to bind to AT2 receptors but at 1000
g/kg/min (plasma levels 2.2 MM) to bind to 80% of the available
AT1 population. These results therefore suggest that AT2 recep-
tors are not involved in the control of renal function, at least in the
anesthetized rat. It remains to be determined whether this is also
the case in other species.
Summary
The actions of Ang II are mediated by at least two specific
subtypes of receptor termed AT1 and AT2. The presence or ratio
of AT1 to AT2 receptors within the kidney varies between species.
In man only one form of the AT1 receptor subtype is expressed
whereas in the rat at least three closely related isoforms are
expressed. The AT1 receptor mediates essentially all of the known
effects of Ang II on the kidney. Both the AT1 receptor and
particularly the AT2 receptor are expressed in large numbers in
the fetal kidney where they may play a role in growth and
differentiation. In some species AT2 receptors disappear from the
kidney shortly after birth. In those species where they remain their
role in the control of renal function has not been clearly defined.
Additional work is needed to define the properties, intracellular
mediators and pharmacological characteristics of intrarenal Ang
II receptors.
Repnnt requests to Marc de Gasparo, MD., Pharma Research Depart-
ment, CIBA-GEIGY Limited, Basel CH 4002, Switzerland.
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